肥厚型心肌病治疗中的房颤风险解析与CMI临床安全考量

*仅供医学专业人士阅读参考

从发病机制到用药思路，一文理清肥厚型心肌病合并房颤的全流程管理，解答临床最关心的问题。

肥厚型心肌病（HCM）是临床最常见的遗传性心肌病之一，在其自然病程中，心房颤动（AF）是发生率最高的心律失常[1]。房颤的出现不仅标志着HCM的疾病进展，更会显著加重患者的症状负担，升高血栓栓塞与心力衰竭事件的发生风险，对患者远期预后产生深远影响[1]。因此，深入理解HCM合并房颤的流行病学特征、病理生理机制与预后意义，明确新兴治疗手段对房颤的影响，对于临床医生优化疾病管理、改善患者结局具有重要价值。

参考文献：

[1] Choi YJ, Lakdawala NK. Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy. J Cardiovasc Imaging. 2025 Aug 25;33(1):12.

[2] Liu M, et al. Distinct mechanistic features of atrial fibrillation in hypertrophic cardiomyopathy. Heart Rhythm. 2026 May 7:S1547-5271(26)02241-1.

[3] Alphonse P, Virk S, Collins J, et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review. Clin Res Cardiol. 2021;110 (4):544-554.

[4] Siontis KC, Geske JB, Ong K, et al. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High-Risk Population. J Am Heart Assoc. 2014;3 (3):e001002.

[5] 《心肌肌球蛋白抑制剂药物治疗专家共识》工作组. 心肌肌球蛋白抑制剂药物治疗专家共识. 药物不良反应杂志. 2026, 28(3): 145-156.

[6] Olivotto I, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. -Supplementary Materials.

[7] Tian Z, et al. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. 2023;8(10):957-965.

[8] Desai MY, et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022;80(2):95-108.

[9] Maron MS, et al. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34-45.

[10] Maron MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024;390(20):1849-1861.

[11] Garcia-Pavia P, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45(47):5071-5083.

[12] Desai MY, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. Circulation. 2025;151(19):1378-1390.

[13] Tower-Rader A, et al. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. Published online March 5, 2026.

[14] Davis BJ, et al. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025 Mar 18;14(6):e038758.

[15] Castrichini M, et al. Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten. Heart Rhythm, 2024, 21(10): 2065-2067.

[16] Nguyen O, et al. Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study. medRxiv, 2025: 2025.09.15.25335783.

[17] Boyle TA, et al. Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes. JACC Clin Electrophysiol. 2025;11(2):411-413.

[18] Bukhari S, et al. New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten. Heart Rhythm. 2026 Apr 23:S1547-5271(26)02283-6.

[19]Rowin E J, et al. Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials[J]. Heart Rhythm, 2026, 23(1): 212-214.

[20] Walklate J, et al. Alpha and beta myosin isoforms and human atrial and ventricular contraction. Cell Mol Life Sci. 2021 Dec;78(23):7309-7337.

[21] Ferrantini C, et al. Mavacamten depresses human atrial contractility in the same EC50% range as human ventricle. Biophysical Journal, 2022, 121(S1): 106a-107a.

[22] Feng M, et al. Cardiac Chamber-Specific Regulation of Myosin Biochemical Super-Relaxation and Auto-Inhibition. FASEB J. 2025;39(22):e71265.

[23] Nag S, et al. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients. Sci Adv. 2023;9(30):eabo7622.

[24] Triposkiadis F, et al. Global left atrial failure in heart failure. European Journal of Heart Failure. 2016;18(11):1307-1317.

[25] Mandoli GE, et al. The Central Role of Left Atrium in Heart Failure. Journal of Clinical Medicine. 2021;10(19):4512.

[ MAT-CN-2604251 V3.0 预计批准日期：2026年8月]
本编号仅作为赛诺菲对本文章所涉及的赛诺菲相关药物所属治疗领域科学和临床数据来源真实性的确认，不作为赛诺菲对本文章全部内容准确性、时效性和完整性的确认和保证

医学界心血管领域交流群正式开放！

加入我们吧！

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。